Agreement Strengthens Pfizer's Neuroscience Research Commitment With Focus
              on Potential Treatments for Alzheimer's Disease

    NEW YORK and HIGH POINT, N.C., Sept. 18 /PRNewswire-FirstCall/ --
Pfizer Inc (NYSE: PFE) and TransTech Pharma, Inc. announced today that they
have entered into a license agreement for the development and
commercialization of small and large molecule compounds under development
by TransTech. These compounds target the receptor for advanced glycation
end products (RAGE) and have potential use in the treatment of Alzheimer's
disease, a progressive illness that kills nerve cells in the brain
afflicting some 18 million people worldwide.
    Through the collaboration, Pfizer gains exclusive worldwide rights to
develop and commercialize TransTech's portfolio of RAGE modulators. The
most advanced molecules are: TTP488, an orally available small-molecule
compound that has completed a Phase 2a study in Alzheimer's patients and is
currently in a Phase 2 study in patients with diabetic nephropathy; and
TTP4000, a large-molecule compound that is expected to enter Phase 1
clinical trials before the end of 2006.
    Under the agreement, TransTech will receive upfront and near-term
milestone payments of $155 million and the potential for significant
additional milestone payments for the successful development and
commercialization of multiple RAGE antagonists in several indications.
TransTech will also receive royalties on worldwide sales of products.
Pfizer will provide TransTech additional funding during the research term
to support continued expansion of the RAGE portfolio. The agreement is
subject to clearance by the U.S. Federal Trade Commission.
    "This agreement is an important step in Pfizer's commitment to
neurosciences research and the development of new medicines for patients
whose lives are impacted by Alzheimer's disease and other disorders," said
Martin Mackay, Ph.D., Pfizer senior vice president Worldwide Research and
Technology. "As a world leader in Alzheimer's disease therapy, we
understand the need for new treatment options for this debilitating disease
which takes an enormous toll on our aging and elderly population."
    "Our collaboration with TransTech advances our strategy to build upon
Pfizer's broad internal research programs with high-potential, externally
sourced product candidates and technologies. With this agreement, we have
now signed 10 major deals for new products and technologies in a number of
therapeutic areas in the last year and our goal is to accelerate this
activity by quickly seizing on new opportunities," added Mackay.
    "We are extremely pleased and excited to be partnering our RAGE
platform with Pfizer," said Adnan M. Mjalli, Ph.D., Founder, president and
chief executive officer of TransTech Pharma. "We believe this transaction
has the potential to be among the largest of its kind in recent years.
Pfizer's deep commitment in multiple therapeutic areas coupled with their
broad expertise and experience in the development and commercialization of
new medicines, especially for the treatment of central nervous system
diseases, were significant factors in our decision to go with Pfizer as the
partner of choice to advance our current portfolio of RAGE inhibitors in a
variety of potential indications."
    TransTech Pharma, Inc. is a majority-owned affiliate of MacAndrews &
Forbes Holdings Inc., whose sole shareholder is Ronald O. Perelman.
    About RAGE
    The receptor for advanced glycation end products (RAGE) is a member of
the immunoglobulin super family of cell surface molecules with a variety of
ligands that are associated with different diseases. Ligands of RAGE and
their associated diseases include:
    -- amyloid fibrils - Alzheimer's disease;
    -- advanced glycation end products (AGEs) - diabetes and renal
       insufficiency;
    -- amphoterin - tumors;
    -- S100/calgranulins - inflammation.

    Pfizer Inc: Working for a healthier world(TM)
    Founded in 1849, Pfizer is the world's largest research-based
pharmaceutical company taking new approaches to better health. We discover
and develop innovative medicines to treat and help prevent disease for both
people and animals. Through consistent, high-quality manufacturing and
distribution operations, our medicines reach patients in 180 nations. We
also partner with healthcare providers, governments and local communities
around the world to expand access to our medicines and to provide better
quality healthcare and health system support. At Pfizer, our colleagues
work every day to help people stay happier and healthier longer and to
reduce the human and economic burden of disease worldwide.
    About TransTech Pharma
    TransTech Pharma is a privately held clinical-stage pharmaceutical
company focused on the discovery, development, and commercialization of
human therapeutics to fill unmet medical needs. The Company's
high-throughput drug discovery platform, Translational Technology(R),
translates the functional modulation of human proteins into safe and
effective medicines. TransTech has a pipeline of small molecule clinical
and pre-clinical drug candidates for the treatment of a wide range of human
diseases, including cardiovascular disorders, central nervous system
disorders, type I/II diabetes, obesity and cancer. For further company
information, visit http://www.ttpharma.com.
    PFIZER DISCLOSURE NOTICE: The information contained in this release is
as of September 18, 2006. Pfizer assumes no obligation to update any
forward- looking statements contained in this release as the result of new
information or future events or developments.
    This release contains forward-looking information about a license
agreement between Pfizer Inc. and TransTech Pharma, Inc. and about possible
product candidates that may be developed from TransTech's portfolio of RAGE
modulators and the potential benefits of such product candidates. This
information involves substantial risks and uncertainties including, among
other things, the satisfaction of conditions to closing the agreement; the
uncertainties inherent in research and development activities; decisions by
regulatory authorities regarding whether and when to approve any drug
applications for product candidates that may be developed from TransTech's
portfolio of RAGE modulators as well as their decisions regarding labeling
and other matters that could affect the availability or commercial
potential of any such product candidates; and competitive developments.
    A further list and description of risks and uncertainties can be found
in Pfizer's Annual Report on Form 10-K for the fiscal year ended December
31, 2005 and in its reports on Form 10-Q and Form 8-K.

Link to this page:

  

http://www.prnewswire.com/comp/688250.html/
CONTACT:
Paul Fitzhenry of Pfizer Inc,
+1-212-733-4637; or Stephen L. Holcombe, Senior Vice President
and Chief Financial Officer of TransTech Pharma, Inc.,
+1-336-841-0300 ext 150, sholcombe@ttpharma.com

---

---

Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996- PR Newswire Association LLC. All Rights Reserved.
A United Business Media company.